In this study, we identified PDGFRA CN gain as a prognostic risk factor for a significantly shorter overall survival (OS) in six cancer species, including adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), sarcoma (SARC), skin cutaneous melanoma (SKCM), and uterine corpus endometrial carcinoma (UCEC). Here, PDGFRA is linked to cancer.